BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roth D, Bloom RD, Molnar MZ, Reese PP, Sawinski D, Sise ME, Terrault NA. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. Am J Kidney Dis 2020;75:665-83. [PMID: 32279907 DOI: 10.1053/j.ajkd.2019.12.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Li C, Liang J, Xiang H, Chen H, Tian J. Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C. Medicine (Baltimore) 2020;99:e23384. [PMID: 33235113 DOI: 10.1097/MD.0000000000023384] [Reference Citation Analysis]
2 Hsu WT, Yang DH, Liao CC, Chen JW, Hsu WH, Kuo CW, Hsu HC, Chang SH, Chen LM. Blood Glucose and Renal Function Evaluation in Patients with Viral Hepatitis. Diabetes Metab Syndr Obes 2021;14:3337-44. [PMID: 34321900 DOI: 10.2147/DMSO.S303252] [Reference Citation Analysis]
3 Kulkarni AV, Duvvuru NR. Management of hepatitis B and C in special population. World J Gastroenterol 2021; 27(40): 6861-6873 [PMID: 34790011 DOI: 10.3748/wjg.v27.i40.6861] [Reference Citation Analysis]
4 Kamar N, Morales JM, Gordon CE, Balk EM, Jadoul M, Martin P; KDIGO HCV Work Group. Response to the KDOQI US Commentary on the 2018 KDIGO Hepatitis C Guideline. Am J Kidney Dis 2021;77:152. [PMID: 32891626 DOI: 10.1053/j.ajkd.2020.07.014] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Azhar A, Binari LA, Joglekar K, Tsujita M, Talwar M, Balaraman V, Bhalla A, Eason JD, Hall IE, Rofaiel G, Forbes RC, Shaffer D, Concepcion BP, Molnar MZ. Association between ezetimibe usage and hepatitis C RNA levels in uninfected kidney transplant recipients who received hepatitis C infected kidneys. Clin Transplant 2021;:e14485. [PMID: 34523744 DOI: 10.1111/ctr.14485] [Reference Citation Analysis]
6 Reese PP, Bloom RD, Roth D; KDOQI HCV Commentary Work Group. In Reply to 'Response to the KDOQI US Commentary on the 2018 KDIGO Hepatitis C Guideline'. Am J Kidney Dis 2021;77:152-3. [PMID: 32891628 DOI: 10.1053/j.ajkd.2020.08.001] [Reference Citation Analysis]
7 D'Marco L, Puchades MJ, Serra MÁ, Gandía L, Romero-Alcaide S, Giménez-Civera E, Molina P, Panizo N, Reque J, Gorriz JL. SARS-CoV-2 vs. Hepatitis Virus Infection Risk in the Hemodialysis Population: What Should We Expect? Int J Environ Res Public Health 2021;18:5748. [PMID: 34071948 DOI: 10.3390/ijerph18115748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yu L, Shen S, Zu Y, Huang J, Li H, Wang S. Hepatitis C virus and carpal tunnel syndrome in hemodialysis patients: a single center cross-sectional study. Ren Fail 2020;42:1076-82. [PMID: 33070671 DOI: 10.1080/0886022X.2020.1832522] [Reference Citation Analysis]
9 Yan L, Li P, Wang Y, Han D, Li S, Jiang M, Cao X, Cao F. The Incremental Prognostic Value of the Clinical Residual SYNTAX Score for Patients With Chronic Renal Insufficiency Undergoing Percutaneous Coronary Intervention. Front Cardiovasc Med 2021;8:647720. [PMID: 33937361 DOI: 10.3389/fcvm.2021.647720] [Reference Citation Analysis]